Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

12.26 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

5 Top Stocks Cathie Wood Is Buying Right Now ↗

September 19, 2022

Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies.

Via InvestorPlace

SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To Know ↗

September 19, 2022

SVB Leerink has decided to maintain its Outperform rating of Intellia Therapeutics (NASDAQ:NTLA) and raise its price target from $152.00 to $158.00. Shares of Intellia Therapeutics are trading down...

Via Benzinga

What 4 Analyst Ratings Have To Say About Intellia Therapeutics ↗

September 19, 2022

Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:

Via Benzinga

This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedEx ↗

September 19, 2022

Wells Fargo lowered the price target for Adobe Inc. (NASDAQ: ADBE) from $425 to $310. Adobe shares fell 1.2% to $296.04 in pre-market trading.

Via Benzinga

Why Is Applied Optoelectronics (AAOI) Stock Up 35% Today? ↗

September 16, 2022

Applied Optoelectronics (AAOI) stock is climbing higher on Friday after the company revealed a $150 million asset sale and new brand launch.

Via InvestorPlace

Intellia Therapeutics Shares Are Gaining After Positive Data From Second CRISPR Candidate ↗

September 16, 2022

Via Benzinga

Expert Ratings for Intellia Therapeutics ↗

September 01, 2022

Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Expert Ratings for Intellia Therapeutics ↗

August 05, 2022

Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:

Via Benzinga

Why Is Esports Entertainment (GMBL) Stock Down 45% Today? ↗

September 16, 2022

Esports Entertainment (GMBL) stock is falling hard on Friday after the company revealed the pricing of a public stock offering.

Via InvestorPlace

What Is Going on With Intellia Therapeutics (NTLA) Stock Today? ↗

September 16, 2022

Intellia Therapeutics (NTLA) stock is on the move Friday after releasing positive clinical trial data for two of its drugs.

Via InvestorPlace

Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies ↗

September 16, 2022

Via Benzinga

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗

September 16, 2022

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

Via Investor's Business Daily

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

Recap: Intellia Therapeutics Q2 Earnings ↗

August 04, 2022

Intellia Therapeutics (NASDAQ:NTLA) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

September 01, 2022

Via Benzinga

Intellia Gets FDA Orphan Drug Status For Hereditary Angioedema Candidate ↗

September 01, 2022

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ: NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE)....

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗

September 01, 2022

Upgrades

Via Benzinga

Where Intellia Therapeutics Stands With Analysts ↗

September 01, 2022

Over the past 3 months, 5 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 26, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Macy's, Palo Alto Networks And Other Big Gainers From Tuesday ↗

August 24, 2022

U.S. stocks closed mostly lower with the Dow Jones dropping more than 150 points on Tuesday. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher ↗

August 17, 2022

These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.

Via InvestorPlace

Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday ↗

August 24, 2022

Gainers

Via Benzinga

7 Stock Price Predictions That Are Actually Worth Listening To ↗

August 12, 2022

Investors may take advantage of analyst stock price predictions beyond the recent share price to discover promising investments.

Via InvestorPlace

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗

August 05, 2022

Shares of Pfizer's rumored takeover target have rocketed for two days running.

Via Investor's Business Daily

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug ↗

August 05, 2022

The company will compete with Pfizer, which already has an approved drug.

Via Investor's Business Daily

Clorox, Crocs And Some Other Big Stocks Moving Lower On Thursday ↗

August 04, 2022

AMTD Digital Inc. (NYSE: HKD) dipped 43.6% to $620.00 on possible profit taking after the stock surged over the last few trading days.

Via Benzinga

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned ↗

August 04, 2022

Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients.

Via Investor's Business Daily

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗

August 03, 2022

Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.

Via InvestorPlace

7 Cathie Wood Stocks Trading at a Discount Right Now ↗

July 26, 2022

These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments.

Via InvestorPlace

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.